<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7280">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939874</url>
  </required_header>
  <id_info>
    <org_study_id>TROP</org_study_id>
    <nct_id>NCT00939874</nct_id>
  </id_info>
  <brief_title>Switch From Tenofovir to Raltegravir for Low Bone Mineral Density</brief_title>
  <acronym>TROP</acronym>
  <official_title>Switch From Tenofovir to Raltegravir for Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's Hospital, Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holdsworth House Medical Practice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St Vincent's Hospital, Sydney</source>
  <oversight_info>
    <authority>Australia: Therapeutic Goods Administration (TGA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if low bone mineral density (a measurement of how
      thick and strong bones are) improves in adults with HIV infection who switch their HIV
      medication tenofovir to another HIV medication raltegravir.

      Hypothesis:That Bone Mineral Density (BMD) will improve in osteopenic or osteoporotic
      patients switching from ART including tenofovir disoproxil fumarate (TDF) and a
      ritonavir-boosted protease inhibitor (r/PI) to ART including RAL+r/PI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) of Lumbar Spine and Hips</measure>
    <time_frame>from Baseline to Weeks 48 and 96</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent Change in Bone Mineral Density of Lumbar Spine and Hips from Baseline to Weeks 48 and 96</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV Viral Load &lt;50 Copies/mL</measure>
    <time_frame>from Baseline to Week 96</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma HIV viral load remained &lt;50 copies/mL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>HIV</condition>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
    <other_name>MK-0518</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. provision of written, informed consent

          2. HIV-infected adults at least 18 years of age

          3. receiving stable ART including TDF and a r/PI for the previous 6 months

          4. no prior PI genotypic resistance or known replication of HIV in patients receiving a
             PI

          5. plasma HIV RNA &lt; 50 copies/ml for at least the previous 3 months

          6. spine or neck of femur t-score â‰¤ -1.0 (i.e. WHO-defined osteopenia) measured by dual
             energy x-ray absorptiometry (DEXA)

             Exclusion Criteria:

          7. participation in any other clinical trial (unless approved by the study PI)

          8. use of TDF for previously active chronic hepatitis B infection

          9. receiving or requiring therapy for low BMD (including prior fragility fracture)

         10. using oral corticosteroids or inhaled fluticasone

         11. virological failure on, or intolerance to, RAL

         12. contra-indication to RAL therapy (see appendix 2)

         13. breast-feeding

         14. pregnancy

         15. secondary, endocrinological cause of low BMD:25-hydroxy vitamin D deficiency,
             hypogonadism: a)symptomatic b)asymptomatic defined by total testosterone &gt; 25% below
             lower limit of reference range and/or luteinizing hormone &gt; 2 x upper limit of normal
             (ULN),untreated hypothyroidism or hyperparathyroidism according to local reference
             ranges
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D Carr, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincents Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Sydney Doctors</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 28, 2015</lastchanged_date>
  <firstreceived_date>July 14, 2009</firstreceived_date>
  <firstreceived_results_date>January 13, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's Hospital, Sydney</investigator_affiliation>
    <investigator_full_name>Andrew Carr</investigator_full_name>
    <investigator_title>Professor, Head Clinical Research program</investigator_title>
  </responsible_party>
  <keyword>HIV+</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>osteopenia</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>bone markers</keyword>
  <keyword>treatment experienced</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir</title>
          <description>Thirty seven adults receiving tenofovir (TDF) and a ritonavir-boosted protease inhibitor (r/PI) were switched from TDF to raltegravir (RAL) in this open-label, non-randomised trial. Raltegravir tablet 400mg was taken orally, twice daily for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 48</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir</title>
          <description>Raltegravir: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50" lower_limit="30" upper_limit="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Bone Mineral Density (BMD) of Lumbar Spine and Hips</title>
        <description>Percent Change in Bone Mineral Density of Lumbar Spine and Hips from Baseline to Weeks 48 and 96</description>
        <time_frame>from Baseline to Weeks 48 and 96</time_frame>
        <safety_issue>No</safety_issue>
        <population>Week 48 data were available for 37 completed participants and Week 96 data were available for 32 completed participants. Fifteen of the enrolled 52 participants were screen failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Thirty seven adults receiving tenofovir (TDF) and a ritonavir-boosted protease inhibitor (r/PI) were switched from TDF to raltegravir (RAL) in this open-label, non-randomised trial. Raltegravir tablet 400mg was taken orally, twice daily for 48 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Bone Mineral Density (BMD) of Lumbar Spine and Hips</title>
            <description>Percent Change in Bone Mineral Density of Lumbar Spine and Hips from Baseline to Weeks 48 and 96</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Spine BMD, week 48 (n=37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.7" lower_limit="1.6" upper_limit="3.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Spine BMD, week 96 (n=32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" lower_limit="1.8" upper_limit="4.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total hip BMD week 48 (n=37)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" lower_limit="1.4" upper_limit="3.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total hip BMD week 96 (n=32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.9" lower_limit="1.1" upper_limit="2.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV Viral Load &lt;50 Copies/mL</title>
        <description>Plasma HIV viral load remained &lt;50 copies/mL</description>
        <time_frame>from Baseline to Week 96</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Week 96 data were available for 32 completed participants</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Thirty seven adults receiving tenofovir (TDF) and a ritonavir-boosted protease inhibitor (r/PI) were switched from TDF to raltegravir (RAL) in this open-label, non-randomised trial. Raltegravir tablet 400mg was taken orally, twice daily for 48 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With HIV Viral Load &lt;50 Copies/mL</title>
            <description>Plasma HIV viral load remained &lt;50 copies/mL</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>at 48 and 96 weeks</time_frame>
      <desc>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir</title>
          <description>Thirty seven adults receiving tenofovir (TDF) and a ritonavir-boosted protease inhibitor (r/PI) were switched from TDF to raltegravir (RAL) in this open-label, non-randomised trial. Raltegravir tablet 400mg was taken orally, twice daily for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>HOSPITAL ADMISSION FOR MALENA AND FEVERS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RIGHT FLANK/QUADRANT PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>PROBABLE LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>PARTNER PREGNANCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>LEFT KIDNEY STONES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>LOWER REPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Cramps</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institution, its personnel and the Principal Investigator must not Publish or present any aspect of the Study without the prior written approval of the sponsor. This includes periodic information releases and announcements to the news media or a third party regarding the progress of this Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Andrew Carr</name_or_title>
      <organization>St Vincents Hospital</organization>
      <phone>+61 2 8382 3359</phone>
      <email>andrew.carr@svha.org.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
